From rodents to recovery: Development of animal models of schizophrenia

CNS Drugs

Volumn 9, Issue 1, 1998, Pages 59-68

  Higgins, Guy A ^a,b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; COGNITION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; HIPPOCAMPUS; LATENT INHIBITION; LIGAND BINDING; NEUROLOGIC DISEASE; NEUROTRANSMITTER RELEASE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; REVIEW; SCHIZOPHRENIA; SOCIAL ISOLATION; SYMPTOMATOLOGY;

EID: 0031952598     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809010-00006     Document Type: Review

References (49)

1. Willner P. The validity of animal models of depression. Psychopharmacology 1984; 83: 1-16
2. Seeman P. Brain dopamine receptors. Pharmacol Review 1980; 32: 229-313
3. Snyder SH. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Am J Psychiatry 1976; 133: 197-202
4. Kornetsky C. Animal models: promises and problems. In: Hanin I. Usdin E. editors. Animal models in psychiatry and neurology. New York: Pergamon Press, 1977: 1-7
5. Ljunberg T, Ungerstedt U. Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: evidence for two different mechanisms of action. Psychopharmacology 1978; 56: 239-47
6. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991; 17: 263-87
7. Goldstein JM. Pre-clinical pharmacology of new atypical antipsychotics in late stage development. Exp Opin Invest Drugs 1995; 4: 291-8
8. 2A receptors in antipsychotic activity. Life Sci 1995; 56: 2209-22
9. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53: 281-98
10. Bleuler E. Dementia praecox. New York: International University Press, 1950
11. McKinney WT. Models of mental disorders: a new comparative psychiatry. New York: Plenum Press, 1988
12. Swerdlow NR, Braff DL, Taaid N, et al. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994; 51: 139-54
13. Feldon J, Weiner I. From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia. J Psychiatr Res 1992; 26: 345-66
14. Gray JA, Feldon J, Rawlins JNP, et al. The neuropsychology of schizophrenia. Behav Brain Sci 1991; 14: 56-84
15. Frith CD, Done DJ. Stereotyped responding by schizophrenic-patients on a two-choice guessing task. Psychol Med 1983; 13: 779-86
16. Randrup A, Munkvad I. Stereotyped activity in several species animal species including man. Psychopharmacologia 1967; 11: 300-10
17. Evenden JL, Robbins TW. Increased response switching, perseveration and perseverative switching following d-amphetamine in the rat. Psychopharmacology 1983; 80: 67-73
18. Ridley RM, Baker HF, Frith CD, et al. Stereotyped responding on a two-choice guessing task by marmosets and humans treated with amphetamine. Psychopharmacology 1988; 95: 560-4
19. Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behav Pharmacol 1990; 1: 469-90
20. Rigdon GC, Viik K. Prepulse inhibition as a screening test for potential antipsychotics. Drug Dev Res 1991; 23: 91-9
21. Varty GB, Higgins GA. Examination of drug-induced and isolation-induced disruptions of prepulse inhibition as models to screen antipsychotic drugs. Psychopharmacology 1995; 122: 15-26
22. Varty GB, Higgins GA. Reversal of a dizocilpine-induced disruption of prepulse inhibition of an acoustic startle response by the 5-HT2 receptor antagonist ketanserin. Eur J Pharmacol 1995; 287: 201-5
23. Weinberger DR, Torrey EF, Neophytides A, et al. Lateral cerebral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry 1979; 36: 735-8
24. Suddath RL, Christison GW, Torrey EF, et al. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990; 322: 789-94
25. Weinberger DR. Schizophrenia: from neuropathology to neurodevelopment. Lancet 1995; 346: 552-7
26. Roberts GW. Schizophrenia: the cellular biology of a functional psychosis. Trends Neurosci 1990; 13: 207-11
27. Rakic P. Specification of cerebral cortical areas. Science 1988; 241: 170-6
28. Goldman-Rakic PS, Selemon LD, Schwartz ML. Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in rhesus monkey. Neuroscience 1984; 12: 719-43
29. Wolkin A, Sanfilipo M, Wolfi AP, et al. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992; 49: 959-65
30. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in the rat. Nature 1980; 286: 74-7
31. Lipska BK, Jaskiw GE, Chrapusta S, et al. Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. Brain Res 1992; 585: 1-6
32. Lipska BK, Swerdlow NR, Geyer MA, et al. Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology 1995; 122: 35-43
33. Kornetsky C, Markowitz A. Animal models of schizophrenia. In: Lipton MA, DiMascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven Press, 1978: 583-93
34. Jones GH, Hernandez TD, Kendall DA, et al. Dopaminergic and serotonergic function following isolation rearing in rats: study of behavioural responses and postmortem and in vivo neurochemistry. Pharmacol Biochem Behav 1992; 43: 17-35
35. Sahakian BJ, Robbins TW, Iversen SD. The effects of psychomotor stimulants on locomotor activity and stereotypy in socially deprived and control rats. Brain Res 1975; 84: 195-205
36. Wright IK, Ismail H, Upton N, et al. Effect of isolation on 5-HT agonist-induced responses in the rat. Psychopharmacology 1991; 105: 259-63
37. Morgan MJ, Einon DF, Nicholas D. The effects of isolation rearing on behavioural inhibition in the rat. Q J Exp Psychol 1975; 27: 615-34
38. Geyer MA, Wilkinson LS, Humby T, et al. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 1993; 34: 361-72
39. Krystal JH, Seibyl JP, Price LH, et al. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Arch Gen Psychiatry 1993; 50: 624-35
40. Varty GB, Higgins GA. Reduced synaptophysin immunoreactivity in the hippocampus of PPI-deficient, isolation reared rats. J Psychopharmacology 1996; 10 Suppl.: A24
41. Eastwood SL, Harrison PJ. Decreased synaptophysin in the medial temporal lobe in schizophrenia demonstrated using immunoautodiography. Neuroscience 1995; 69: 339-43
42. Bristow LJ, Kramer MS, Kulagowski J, et al. Schizophrenia and L-745870, a novel dopamine D4 receptor antagonist. Trends Neurosci 1997; 18: 186-8
43. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 1992; 49: 206-15
44. Fray PJ, Robbins TW, Sahakian BJ. Neuropsychiatric applications of CANTAB. Int J Geriatr Med 1996; 11: 329-36
45. ODonovan MC, Owen MJ. Molecular genetics of schizophrenia. Ann Med 1996; 28: 541-6
46. Williams J, Spurlock G, McGuffin P, et al. Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. Lancet 1996; 347: 1294-6
47. Ross CA, Pearlson GD. Schizophrenia, the heteromodal association neocortex and development: potential for a neurogenic approach. Trends Neurosci 1996; 19: 171-6
48. Lijam N, Paylor R, McDonald MP, et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dv11. Cell 1997; 90: 895-905
49. Paylor R, Crawley J. Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology 1997; 132: 169-80